BC
CNCE

Broadfin Capital’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Broadfin Capital’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-200,000
Closed -$2.69M – 85
2014
Q1 		$2.69M Buy
+200,000
New +$2.82M 0.26% 75

Other funds holding CNCE

BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Broadfin Capital's CNCE Position: Q2 2014 in Review

Broadfin Capital sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2014, closing a stake of 200,000 shares — an estimated $2.69M sold.

Broadfin Capital first reported a position in CNCE in Q1 2014 and held it in 1 quarter. The position peaked at $2.69M in Q1 2014. 50 funds tracked by Wall St. Rank hold CNCE as of Q2 2014.

  • Broadfin Capital reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Broadfin Capital sold 200,000 Concert Pharmaceuticals, Inc. shares in Q2 2014, an estimated $2.69M.
  • Broadfin Capital first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • Broadfin Capital's Concert Pharmaceuticals, Inc. position peaked at $2.69M in Q1 2014.
  • 50 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2014.

Based on Broadfin Capital's 13F filing for Q2 2014, filed 14 Aug 2014.